Prostate cancer trends in Latvia during 1990-2012: Incidence, prevalence, mortality, and survival rates

Medicina (Lithuania)

Volumn 50, Issue 6, 2014, Pages 313-317

  Plonis, Juris ^a   Bokums, Kristaps ^a   Cauce, Vinita ^b   Miklasevics, Edvins ^a   Vaganovs, Peteris ^a   Irmejs, Arvids ^a   Gardovskis, Janis ^a   Vjaters, Egils ^a  

^a PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

Author keywords

Epidemiology; Prostate cancer; Prostate cancer treatment; Survival rates

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LATVIA; MALE; MIDDLE AGED; MORTALITY; PREVALENCE; PROSTATIC NEOPLASMS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LATVIA; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84923775717     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medici.2014.11.002     Document Type: Article

References (14)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 2012;62:283-98.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Powell IJ, Banerjee M, Bianco FJ, Wood Jr DP, Dey J, Lai Z, et al. The effect of race/ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data. J Urol 2004;171:1508-12.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
5. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010;46:3040-52.
6. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92.
7. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: A new WHO standard. http://www.who.int/healthinfo/paper31.pdf.
8. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-51. correction: 2001;20:655.
9. Forman D, Stockton D, Moller H, Quinn M, Babb P, De Angelis R, Micheli A. Cancer prevalence in the UK: results from the EUROPREVAL study. Ann Oncol 2003;14:648-54.
10. Micheli A, Mugno E, Krogh V, Quinn MJ, Coleman M, Hakulinen T, et al. Cancer prevalence in European registry areas. Ann Oncol 2002;13:840-65.
11. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004;119:174-86.
12. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. ERSPC Investigators: screening and prostatecancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-8.
13. Paquette EL, Sun L, Paquette LR, Connelly R, McLeod DG, Moul JW. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002;60:756-9.
14. Popiolek Ml, Rider JR, Andrén O, Andersson SO, Holmberg L, Adami HO, Johansson JE. Natural history of early, localized prostate cancer: a final report from three decades of followup. Eur Urol 2013;63(3):428-35.